# Rationale for the probabilities

## Evidence and information boundary

This is a cert-stage, CVSG-moment forecast for PhRMA v. O'Day, Supreme Court docket 25-1018. I read the provisioned `2026-06-23.json` snapshot, `context.json`, `event.yaml`, and the extracted questions presented, petition, and brief in opposition. The frozen context is forward mode, Term 2025, `sal-v4` high band, two distributions, and a June 22, 2026 CVSG. The snapshot stops before June 23; it is not a representation of the September 18 docket. I did not retrieve the petition's disposition, subsequent history, or current Supreme Court docket, and do not know its outcome.

The document manifest reports nonempty, untruncated petition and opposition texts, 44 and 27 PDF pages respectively. Their July/August fetch dates do not change their February 20 and May 28 filing dates. The June 2 reply and the X.AI amicus brief appear in the snapshot, but their text was not provisioned or consulted. No invited government brief is in this baseline; its recommendation is unknown, not assumed to favor a grant.

I attempted to check the parties' competing descriptions against the August 26, 2025 Ninth Circuit opinion. A date-bounded CourtListener search confirmed the opinion's identity, but the document tool reported that no text was available. Accordingly, the substantive assessment below rests on the parties' briefs, not on an independently read lower-court opinion. General Rule 10 web retrieval also returned no usable material. Neither attempt exposed a Supreme Court outcome.

## Base-rate anchor

The committed `metrics/statpack.md` salience table matches the frozen `sal-v4` definition. Pooling every displayed Term strictly before 2025, namely 2017–2024, gives the high band's bracketed reached rate of **314 / 898 = 34.97%**. I computed this using the corresponding exact `prefix_est_grant_rate` and `prefix_weighted_resolved` values in `metrics/statpack.json`, rather than averaging rounded percentages. Terms 2025 and 2026 are excluded from the anchor.

The paid-segment CVSG cut is an important cross-check: its 163 resolved petitions show 29.4% ordinary grants plus 5.5% GVRs, approximately 34.9% any grant. That is a pooled diagnostic containing all pack Terms, not a separately time-filtered prior or an independent multiplier. The high-band anchor already incorporates heightened docket attention; adding another full CVSG uplift would double count the same signal. The committed pack exposes no build timestamp or corpus-wide pull/snapshot vintage, so these are statistics of the supplied pack, not claims about the current remote corpus. I made no live corpus query.

I also read the paid-segment terminal relist cuts: grant-family shares are approximately 1.7%, 13.3%, 40.9%, and 36.8% for buckets 0, 1, 2, and 3+. These are terminal populations, not forward transition probabilities. In particular, this case's first distribution was followed by a response request, not necessarily a substantive relist. The very high probability of another distribution comes principally from the unfinished CVSG process, not from projecting those terminal buckets mechanically.

## Case-specific adjustment to 43%

There are genuine reasons to place this petition above the approximately 35% anchor. The petition challenges both compelled explanations of pricing decisions and disclosure of trade secrets, not merely the accuracy of a drug-price calculation. It develops a commercial-speech objection backed by Judge Bea's dissent and claims a substantial trade-secret analogy to the First Circuit's Philip Morris decision (petition pp. 11–18, 30–32). The published decision's asserted reach across regulated industries and the Court's progression from a response request to a CVSG support serious consideration. The X.AI filing provides limited evidence of interest beyond the pharmaceutical industry, without establishing what that amicus argued.

The opposition substantially tempers those points. It argues that the commercial-speech holding is contextual rather than a categorical reporting exemption, and that the cited speech decisions concern materially different settings (BIO pp. 8–14). On intermediate scrutiny, the briefs dispute whether the panel relied on a circular transparency rationale or on evidence of practical effects (petition pp. 18–25; BIO pp. 14–17). Without the opinion text, I cannot resolve that disagreement confidently and do not treat either advocate's description as an established holding.

Most importantly, Oregon stresses that the takings ruling rejects a facial challenge, that even the dissent agreed with that result, that some disclosures could be permissible under Monsanto, and that as-applied claims remain available. It identifies an additional ripeness question if the Court reaches the takings merits (BIO pp. 18–22). The petition's contrary framing and its Philip Morris analogy are substantial, but they do not establish an unavoidable circuit conflict on identical facts and procedural posture. The government's interest in protecting federal reporting regimes also makes a CVSG compatible with eventual denial.

The resulting **43%** is a judgmental net increase of about eight percentage points over the prior-Term anchor, not an estimated regression effect. It leaves denial as the modal disposition while recognizing a serious prospect of a narrowed grant. The decisive uncertainty is whether the Court and Solicitor General see a broad conflicting legal rule or a distinguishable facial challenge. No unobserved government recommendation is treated as evidence.

## Other elicited judgments

- **Further distribution, 97%:** ordinarily needed to consider the forthcoming invited brief; the residual allows withdrawal, dismissal, or another path without a recorded distribution increment. The increment is from two, not from zero.
- **New CVSG, 0%:** the invitation already exists. This masked claim is not a probability that the government will file its invited brief.
- **Summary route given grant, 10%:** the two contested constitutional questions favor plenary review; the baseline identifies no intervening decision warranting a specific GVR. The residual allows an unanticipated summary or remand route.
- **Separate writing given denial, 14%:** the constitutional stakes and lower-court dissent make one plausible, but not the expected route. This is an aggregate existence forecast only.
- **Stakes, 0.67:** corporate speech, trade-secret protection, and regulatory transparency have meaningful cross-industry consequences. This score reflects potential significance, not the probability of certiorari or an asserted downstream effect on drug prices.

No votes or merits judgment are supplied because this cell forecasts cert disposition, not a merits decision. Tool limitations are reported in `tooling.json`; they did not block a forecast from the substantial provisioned record.
